Kaituo Pharmaceutical-B (09939) rose by nearly 15%. As of press release, it rose 14.94% to HK$1, with a turnover of HK$81,000.
The Zhitong Finance App learned that Kaituo Pharmaceutical-B (09939) was nearly 15% higher. As of press release, it had risen 14.94% to HK$1, with a turnover of HK$81,000.
According to the news, Pioneer Pharmaceutical announced that its self-developed phase II clinical trial of GT20029 tincture, a novel proteolytic chimeric (PROTAC) compound targeting androgen receptors (AR), was used topically to treat male androgenic alopecia (alopecia or AGA). The results were statistically significant and clinically significant, and the safety and tolerability were good.
The announcement stated that based on the results of this phase II clinical trial, the company will actively deploy clinical strategies for GT20029 follow-up, such as carrying out phase III clinical trials for male hair loss in China and phase II clinical trials in the US. In addition, the company is also preparing to conduct a phase II clinical trial of GT20029 for acne treatment.